{{Rsnum
|rsid=497710
|Gene=INSL5
|Chromosome=1
|position=66799248
|Orientation=plus
|GMAF=0.1175
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=INSL5
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 5.3 | 27.4 | 67.3
| HCB | 0.0 | 0.0 | 100.0
| JPT | 0.0 | 0.0 | 100.0
| YRI | 5.4 | 34.0 | 60.5
| ASW | 3.5 | 28.1 | 68.4
| CHB | 0.0 | 0.0 | 100.0
| CHD | 0.0 | 1.8 | 98.2
| GIH | 0.0 | 22.8 | 77.2
| LWK | 2.7 | 22.7 | 74.5
| MEX | 1.7 | 24.1 | 74.1
| MKK | 0.6 | 28.2 | 71.2
| TSI | 5.9 | 22.5 | 71.6
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs497710
|Name_s=
|Gene_s=INSL5
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: A, MAF= 0.15, combined P value= 2.34E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470214
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs497710
|overall_frequency_n=108
|overall_frequency_d=128
|overall_frequency=0.84375
|n_genomes=52
|n_genomes_annotated=0
|n_haplomes=91
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}
{{on chip | Affy GenomeWide 6}}